Andrew Bulpin to Assume Leadership of Process Solutions at Merck Millipore
News May 02, 2012
Merck Millipore, the Life Science division of Merck, has announced that Andrew Bulpin, Head of Global Pharmaceutical Chemicals Solutions Sales at Merck Millipore has been appointed Head of the company's Process Solutions Business Unit.
He will assume leadership effective May 14, 2012 and be based at the company's U.S. headquarters in Massachusetts.
Bulpin succeeds Jean-Paul Mangeolle, who is retiring from the company after 28 years of distinguished service.
"Andrew brings a wealth of leadership experience and an in-depth understanding of the life science markets," noted Robert Yates, President of Merck Millipore.
Yates continued, "With a continued focus on helping biopharmaceutical and pharmaceutical manufacturers advance their molecules to market, Andrew has an unprecedented opportunity to evolve the Process Solutions business."
Bulpin joined Millipore Corporation in 2006 as Vice President for the Upstream Processing Business Unit and, in January 2012, assumed leadership of the Services and Solutions Business.
Following the company's acquisition by Merck, he was appointed to his current position.
Prior to Merck Millipore, Bulpin worked at Serologicals Corporation in a number of sales and marketing roles both in the U.S. and Europe.
He holds a Ph.D. in organic chemistry from the Université de Caen, France; an MBA from the University of Strathclyde, Scotland; and a BSc from the University of Sussex, England.
Bulpin also worked as a Post-Doctoral Research Fellow at the Australian National University, Australia.
SYGNIS AG Signs Supply Agreement with US Biological for the Lightning-Link Antibody Labelling TechnologyNews
SYGNIS AG, the Group which includes Expedeon Holdings, Innova Biosciences, and C.B.S. Scientific Company, announced it has signed a supply agreement with US Biological, Salem, MA, USA, for its Innova Lightning-Link® technology.READ MORE
Chemists Design More Efficient Microreactor Using 3D PrintingNews
Researchers developed an electrochemical microreactor using additive manufacturing technology (commonly known as 3D printing). The newly developed microreactor was tested on synthesis of isoindolinones, which are found in many natural products, pharmaceuticals, and biologically active molecules.READ MORE
New Bioprocessing Technique Set to Revolutionize Cell CultureNews
A technique which revolutionises cell culture by allowing the continuous production and collection of cells, has been developed by scientists at Newcastle University. The Newcastle team have developed a coating that allows individual stromal cells to “peel away” from the surface on which they are grown.READ MORE